Literature DB >> 28717548

Infective complications in patients after transrectal ultrasound-guided prostate biopsy and the role of ciprofloxacin resistant Escherichia coli colonization in rectal flora.

Mustafa Bilal Hamarat1, Fatih Tarhan2, Rahim Horuz3, Gülfem Akengin Öcal4, Mehmet Kutlu Demirkol2, Alper Kafkaslı5, Özgür Yazıcı2.   

Abstract

OBJECTIVE: In the present study, we aimed to invastigate the ciprofloxacin resistance in rectal flora of the patients undergoing prostate biopsy in our department. Additionally, the possible effects of the presence of ciprofloxacin resistant bacteria in faecal flora on the risk of infective complications after the procedure as well as the effect of antibiotic prophylaxis on such infectious complications have been evaluated.
MATERIAL AND METHODS: A total of 142 patients undergoing transrectal ultrasound-guided prostate biopsy were included into the study program. Rectal swab samples were taken from all patients prior to biopsy. The presence of complications have been evaluated after a week following the biopsy procedure. Patients with fever were also evaluated. The possible correlation between the presence of ciprofloxacin-resistant bacteria in faecal flora and the risk of urinary tract infection development and the other complications were evaluated.
RESULTS: E. coli bacteria were present in all cultures of rectal swab samples obtained from 142 patients prior to prostate biopsy. Of all these patients, while ciprofloxacin-resistant E. coli (CR E. coli) grew in 76 (53.5%) patients; ciprofloxacin susceptible E. coli (CS E. coli) was obtained in 66 (46.5%) patients. In 16 patients (11.3%), infectious complications were observed. While the infective complications were present in the 14.5% of patients with CR E. coli; they were present in the 7.6% of patients with CS E. coli (p=0.295). High fever was observed in nine patients (6.3%). Of these nine patients, although six had CR E. coli growth as detected during culture sensitivity tests; three had CS E. coli growth in their rectal swab culture tests. Sepsis was observed in three (2.1%) of these patients with high fever. Ciprofloxacin-resistant E. coli grew in all of the rectal swab cultures obtained from these patients with sepsis.
CONCLUSION: In the light of our findings we may say that, it will be appropriate to reconsider the ciprofloxacin prophylaxis and prefer to use other prophylactic agents for a certain period of time in populations with higher rates of resistance to this medical agent. Furthermore, it will be appropriate again to obtain rectal swab specimens for culture tests before biopsy procedure in order to perform targeted prophylaxis according to the culture antibiogram test results. This approach will enable us to evaluate the cost-effectiveness of the procedure in detail.

Entities:  

Keywords:  Ciprofloxacin resistance; infective complications; prostate biopsy; rectal flora

Year:  2017        PMID: 28717548      PMCID: PMC5503443          DOI: 10.5152/tud.2017.76390

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  23 in total

1.  Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis?

Authors:  D Steensels; K Slabbaert; L De Wever; P Vermeersch; H Van Poppel; J Verhaegen
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

2.  Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?

Authors:  Jordi Puig; Anna Darnell; Patricia Bermúdez; Antoni Malet; Guadalupe Serrate; Marisa Baré; Joan Prats
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

3.  Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy.

Authors:  Deepak Batura; G Gopal Rao; Peder Bo Nielsen
Journal:  BJU Int       Date:  2010-03-16       Impact factor: 5.588

4.  Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy.

Authors:  Michael A Liss; Stephen A Taylor; Deepak Batura; Deborah Steensels; Methee Chayakulkeeree; Charlotte Soenens; G Gopal Rao; Atreya Dash; Samuel Park; Nishant Patel; Jason Woo; Michelle McDonald; Unwanaobong Nseyo; Pooya Banapour; Stephen Unterberg; Thomas E Ahlering; Hendrik Van Poppel; Kyoko Sakamoto; Joshua Fierer; Peter C Black
Journal:  J Urol       Date:  2014-06-10       Impact factor: 7.450

5.  Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.

Authors:  Oscar Cuevas; Jesús Oteo; Edurne Lázaro; Belén Aracil; Francisco de Abajo; Silvia García-Cobos; Adriana Ortega; José Campos
Journal:  J Antimicrob Chemother       Date:  2010-12-14       Impact factor: 5.790

6.  Is it possible to predict sepsis, the most serious complication in prostate biopsy?

Authors:  Adnan Simsir; Erkan Kismali; Rashad Mammadov; Gurhan Gunaydin; Cag Cal
Journal:  Urol Int       Date:  2010-03-12       Impact factor: 2.089

7.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

8.  Comparison between ciprofloxacin and trimethoprim-sulfamethoxazole in antibiotic prophylaxis for transrectal prostate biopsy.

Authors:  Doğan Atılgan; Yusuf Gençten; Engin Kölükçü; Şahin Kılıç; Nihat Uluocak; Bekir Süha Parlaktaş; Fikret Erdemir
Journal:  Turk J Urol       Date:  2015-03

9.  Complications of transrectal ultrasound-guided 12-core prostate biopsy: a single center experience with 2049 patients.

Authors:  Ozan Efesoy; Murat Bozlu; Selahittin Çayan; Erdem Akbay
Journal:  Turk J Urol       Date:  2013-03

10.  Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

Authors:  D A Kapoor; I W Klimberg; G H Malek; J D Wegenke; C E Cox; A L Patterson; E Graham; R M Echols; E Whalen; S F Kowalsky
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

View more
  1 in total

1.  Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach.

Authors:  Bettina Wulff Risør; Nasrin Tayyari Dehbarez; Jacob Fredsøe; Karina Dalsgaard Sørensen; Bodil Ginnerup Pedersen
Journal:  Appl Health Econ Health Policy       Date:  2022-08-08       Impact factor: 3.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.